DFC (cipher)

Cidara Therapeutics Announces Issuance of First U.S. Patent for CD388

Retrieved on: 
Thursday, December 1, 2022

SAN DIEGO, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced that the U.S. Patent and Trademark Office issued U.S. Patent No.

Key Points: 
  • SAN DIEGO, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced that the U.S. Patent and Trademark Office issued U.S. Patent No.
  • The patent is the first issued for CD388, and includes claims directed to the composition of matter of CD388.
  • The patent is projected to expire in 2039 plus any available patent term extension.
  • We are pleased to receive the first U.S. patent for our lead flu DFC, CD388, as we establish robust IP protection for this new class of drug, said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara.

Cidara Therapeutics Announces Two Leading Independent Proxy Advisory Firms Recommend Stockholders Vote “FOR” Proposed Reverse Stock Split

Retrieved on: 
Tuesday, November 29, 2022

We appreciate the recommendation of two leading independent proxy advisory firms advising our stockholders to vote in favor of the proposed reverse stock split, said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara.

Key Points: 
  • We appreciate the recommendation of two leading independent proxy advisory firms advising our stockholders to vote in favor of the proposed reverse stock split, said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara.
  • ISS and Glass Lewis are independent proxy advisory firms and do not have any business relationship with Cidara.
  • Stockholders of record at the close of business on November 8, 2022 can vote by proxy or online during the Special Meeting.
  • Vote by proxy card: Complete, sign and date the proxy card and return it promptly in the envelope provided.

Mosdex Will Now Support ERC20 USDT

Retrieved on: 
Monday, November 28, 2022

From now on, Mosdex users can deposit or withdraw their USDT ERC-20 Tether.

Key Points: 
  • From now on, Mosdex users can deposit or withdraw their USDT ERC-20 Tether.
  • Their latest announcement supporting ERC20 USDT aims to increase user accessibility and diversity on the Mosdex platform, a prime goal of the platform creators.
  • For instance, if a user is currently holding USDT they deposited using ERC20, the user can withdraw it through the Omni network, eliminating the conversion requirements USDT ERC-20
    ERC20-USDT means Tether-issued USDT on the Ethereum network, compliant with Erc20 standard.
  • During this point, the user has to choose Erc20 using Ethereum Erc20, depending on the network used for depositing or withdrawing USDT.

Cidara Therapeutics and Melinta Therapeutics Announce Publication of Data from the Global Phase 3 Pivotal ReSTORE Trial of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis in The Lancet

Retrieved on: 
Monday, November 28, 2022

SAN DIEGO and PARSIPPANY, N.J., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX) and Melinta Therapeutics, LLC today announced the peer-reviewed publication of data from the completed pivotal ReSTORE Phase 3 clinical trial evaluating the efficacy and safety of its once-weekly antifungal candidate rezafungin as a potential treatment for candidemia and invasive candidiasis. The data, published in The Lancet titled, “Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial,” demonstrate the statistical noninferiority of rezafungin dosed once-weekly, versus the current standard of care caspofungin, dosed once-daily.

Key Points: 
  • We believe that rezafungin could have a significant impact on the lives of patients battling difficult-to-treat and often deadly Candida infections.
  • Melinta announced earlier this year that it had acquired the exclusive rights to commercialize rezafungin in the U.S. from Cidara.
  • The FDA has accepted for filing and granted Priority Review to Cidaras NDA for rezafungin for the treatment of candidemia and invasive candidiasis.
  • Rezafungin is a novel once-weekly echinocandin being developed for both the treatment and prevention of serious fungal infections, such as candidemia and invasive candidiasis.

Cidara Therapeutics to Participate in the World Antiviral Congress 2022

Retrieved on: 
Wednesday, November 23, 2022

SAN DIEGO, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced that Jeff Stein, Ph.D., President and CEO, will participate in a panel discussion at the World Antiviral Congress being held in San Diego, California from November 28-December 1, 2022.

Key Points: 
  • SAN DIEGO, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced that Jeff Stein, Ph.D., President and CEO, will participate in a panel discussion at the World Antiviral Congress being held in San Diego, California from November 28-December 1, 2022.
  • The panel will discuss pandemic preparedness and therapeutic approaches, including predictions on the next viral threat, development of broad-spectrum drugs and platforms to engineer novel therapeutics.
  • Session Date/Time: December 1, 2022, at 8:20 9:30 a.m. PST
    To register and view the full congress schedule, visit the World Antiviral Congress website here .
  • Cidara is developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases.

Cidara Therapeutics to Present at the Stifel Healthcare Conference

Retrieved on: 
Tuesday, November 8, 2022

Cidaras presentation will be available on-demand from the above date/time in theInvestors section on the Companys website at www.cidara.com .

Key Points: 
  • Cidaras presentation will be available on-demand from the above date/time in theInvestors section on the Companys website at www.cidara.com .
  • The replay of the presentation will be available for 90 days.
  • Cidara is developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases.
  • Cidara is headquartered in San Diego, California.

Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results

Retrieved on: 
Thursday, November 3, 2022

SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious diseases, today reported financial results for the third quarter ended September30, 2022 and provided an update on its corporate activities and product pipeline.

Key Points: 
  • SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious diseases, today reported financial results for the third quarter ended September30, 2022 and provided an update on its corporate activities and product pipeline.
  • Announced license agreement with Melinta Therapeutics, LLC: In July 2022, Cidara announced it entered into a license agreement with Melinta Therapeutics, LLC (Melinta) under which Cidara has granted Melinta an exclusive license to commercialize rezafungin in the U.S.
  • Cidara retains the rights to rezafungin in Japan, while Mundipharma retains the commercial rights to rezafungin outside the U.S. and Japan.
  • Presented new data for rezafungin at IDWeek 2022: In October 2022, Cidara presented new clinical and preclinical data for rezafungin in six poster presentations at IDWeek 2022.

Cidara Therapeutics to Present New Data for Rezafungin at IDWeek 2022

Retrieved on: 
Monday, October 17, 2022

QIDP designation is reserved for antibacterial and antifungal drug candidates intended to treat serious or life-threatening infections.

Key Points: 
  • QIDP designation is reserved for antibacterial and antifungal drug candidates intended to treat serious or life-threatening infections.
  • Additionally, rezafungin has been granted Orphan Drug Designation for its use in the treatment of invasive candidiasis in both the U.S. and EU.
  • Cidara retains the rights to rezafungin in Japan and has licensed the commercial rights to Melinta Therapeutics in the U.S. and Mundipharma Medical in all other geographies.
  • Cidara is developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases.

Cidara Therapeutics Announces FDA Acceptance for Priority Review of New Drug Application for Rezafungin for the Treatment of Candidemia and Invasive Candidiasis

Retrieved on: 
Tuesday, September 20, 2022

QIDP designation is reserved for antibacterial and antifungal drug candidates intended to treat serious or life-threatening infections.

Key Points: 
  • QIDP designation is reserved for antibacterial and antifungal drug candidates intended to treat serious or life-threatening infections.
  • Rezafungin is a novel, once-weekly echinocandin antifungal being developed for the treatment of candidemia and invasive candidiasis, as well as for the prophylaxis of invasive fungal infections in patients undergoing allogeneic blood and marrow transplant.
  • Todays announcement is an important step forward for patients fighting difficult-to-treat and often deadly candidemia and invasive candidiasis, and represents a critical milestone for Cidara's rezafungin development program, said Jeff Stein, President, and CEO of Cidara Therapeutics.
  • Rezafungin is a novel once-weekly echinocandin being developed for both the treatment and prevention of serious fungal infections, such as candidemia and invasive candidiasis.

Cidara Therapeutics Announces Initiation of Phase 2a Human Viral Challenge Trial to Evaluate CD388 for Universal Prevention of Influenza

Retrieved on: 
Tuesday, September 13, 2022

SAN DIEGO, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious diseases, today announced the initiation of its Phase 2a trial to evaluate the pre-exposure prophylactic activity of CD388 against influenza virus. CD388 is a highly potent, long-acting antiviral designed to deliver universal prevention of seasonal and pandemic influenza. The study is being conducted under an exclusive worldwide license and collaboration agreement with Janssen Pharmaceuticals, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to develop and commercialize Cidara’s Cloudbreak® drug-Fc conjugates (DFCs) for the prevention of seasonal and pandemic influenza.

Key Points: 
  • CD388 is a highly potent, long-acting antiviral designed to deliver universal prevention of seasonal and pandemic influenza.
  • Multiple dose levels of CD388 will be evaluated in volunteers who will receive a single administration of CD388 or placebo prior to influenza viral challenge.
  • Because of its mode of action, CD388 has the potential to enable universal influenza coverage against all viral strains for all people, including those with compromised immune systems.
  • For influenza, the long-acting CD388 DFC is designed to directly inhibit viral proliferation by targeting a conserved region on the viral envelope, potentially conferring universal prevention of Types A and B influenza with a single seasonal dose.